{"id":27422,"date":"2020-09-28T10:11:26","date_gmt":"2020-09-28T08:11:26","guid":{"rendered":"https:\/\/kymos.com\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/"},"modified":"2026-03-04T21:11:12","modified_gmt":"2026-03-04T20:11:12","slug":"kymos-e-prolytic-si-fondono-per-diventare-kymos-group","status":"publish","type":"post","link":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/","title":{"rendered":"Kymos e Prolytic si fondono per diventare Kymos Group"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3 class=\"\" style=\"--fontsize: 17; line-height: 1.67; --minfontsize: 17;\" data-fontsize=\"17\" data-lineheight=\"28.39px\"><span style=\"font-size: 14pt;\"><strong>Con l&#8217;ingresso della CRO tedesca nel gruppo europeo, Kymos rafforzer\u00e0 la sua attivit\u00e0 nel mercato dei biologici e delle terapie avanzate e amplier\u00e0 il suo portafoglio di servizi, offrendo tre sedi locali in Europa<\/strong><\/span><\/h3>\n<div class=\"blog-content\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p><span style=\"font-size: 14pt;\"><strong>Barcellona, Spagna, e Francoforte, Germania, 28 settembre 2020<\/strong> \u2013 <a href=\"https:\/\/kymos.com\/it\/kymos\/\" data-wpel-link=\"internal\">Kymos S.L<\/a>. e <a href=\"https:\/\/kymos.com\/it\/prolytic\/\" data-wpel-link=\"internal\">Prolytic GmbH<\/a> annunciano oggi il completamento di una riuscita fusione strategica per integrare Prolytic nel Kymos Group, al fine di offrire servizi a valore aggiunto alle aziende biofarmaceutiche di tutto il mondo, con una soluzione veramente paneuropea in un contesto aziendale in rapida evoluzione. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La combinazione di competenze consentir\u00e0 alle aziende di ampliare il loro portafoglio in una selezione unica di servizi per molecole innovative piccole e grandi, generici, biosimilari, anticorpi, biomarcatori, ADA (anticorpi anti-farmaco), ADC (coniugati anticorpo-farmaco), ormoni, enzimi e acidi nucleici. Intensificheranno inoltre la loro attivit\u00e0 nel mercato delle terapie avanzate. L&#8217;interesse per le proteine ricombinanti e per le terapie avanzate cellulari e geniche \u00e8 attualmente in forte espansione in Europa e nel mondo. Prolytic ha acquisito competenze nelle tecnologie mRNA, utilizzate in alcuni dei vaccini anti-Covid-19 pi\u00f9 avanzati in fase di sviluppo in Europa.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Le due aziende, insieme a Pharmaprogress, affiliata del Kymos Group in Italia, condividono un impegno per la qualit\u00e0 e una dedizione all&#8217;innovazione. Mentre i clienti avranno accesso a una gamma ampliata di servizi certificati GMP\/GLP e conformi GCP, continueranno a ottenere un servizio personalizzato, su misura e genuinamente flessibile, che non si trova in nessun&#8217;altra CRO di queste dimensioni. Kymos e Prolytic hanno una comprensione multidisciplinare dell&#8217;intero processo di sviluppo e produzione farmaceutica, dalle fasi di sviluppo e cliniche fino all&#8217;approvazione finale e agli studi post-marketing, garantendo sicurezza logistica e affidabilit\u00e0. La fusione migliorer\u00e0 la capacit\u00e0 dell&#8217;azienda di reagire ancora pi\u00f9 rapidamente alle esigenze specifiche dei suoi clienti globali.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>&#8220;Il mercato odierno vuole fornitori di servizi completi e soluzioni one-stop. Con questa fusione saremo in grado di pensare globalmente e agire localmente, fornendo ai nostri clienti un servizio affidabile, fidato e notevolmente migliorato,&#8221;<\/em> ha dichiarato la dott.ssa Dorothee Krone, amministratore delegato di Prolytic. <em>&#8220;Le aziende piccole e medie si sentono a proprio agio lavorando con noi. Kymos pu\u00f2 aiutarci a coprire l&#8217;intero ciclo delle scienze della vita e ora possiamo offrire una gamma di servizi molto pi\u00f9 diversificata di quanto siamo mai stati in grado di fare in passato.&#8221;<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>&#8220;La conoscenza che Prolytic ha riguardo al DNA e all&#8217;RNA \u00e8 un elemento scientifico chiave del mercato dei servizi per le terapie avanzate in cui Kymos sta entrando,&#8221;<\/em> ha dichiarato il sig. Joan Puig de Dou, CEO di Kymos. <em>&#8220;La fusione ci offre l&#8217;opportunit\u00e0 di aumentare la nostra offerta di servizi, rafforzare il mercato delle terapie emergenti e creare un&#8217;azienda multinazionale e multidisciplinare. Non vediamo l&#8217;ora di affrontare questa nuova fase nella storia dell&#8217;azienda.&#8221;<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Con questa fusione, Kymos ha ora tre sedi in Europa: a Barcellona (Spagna), Ancona (Italia) e Francoforte (Germania). La sede italiana \u00e8 il risultato della fusione del 2016 con Pharmaprogress SRL. In base all&#8217;accordo, i nomi delle aziende rimarranno invariati. Nella sede tedesca di Prolytic, l&#8217;attuale management rimarr\u00e0 in carica, mentre il numero del personale aumenter\u00e0. Verr\u00e0 messo in atto un piano di investimenti per acquisire attrezzature all&#8217;avanguardia.    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Dopo aver rafforzato la sua gi\u00e0 importante presenza nell&#8217;UE, il gruppo europeo punter\u00e0 ad espandersi nella regione Asia-Pacifico, aprendo al contempo nuove promettenti aree terapeutiche.<\/span><\/p>\n<p><strong style=\"font-size: 14pt; color: var(--body_typography-color); font-family: var(--body_typography-font-family); font-style: var(--body_typography-font-style,normal); letter-spacing: var(--body_typography-letter-spacing);\">Informazioni su Prolytic <\/strong><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic GmbH \u00e8 un&#8217;esperta in bioanalisi e farmacocinetica con capacit\u00e0 specializzate di ricerca a contratto in bioanalisi e valutazioni farmacocinetiche secondo GLP e GCP.<\/span><br \/><span style=\"font-size: 14pt;\">Fornisce una gamma di servizi sofisticati nello sviluppo e nella validazione di metodi analitici per l&#8217;analisi e la quantificazione di piccole molecole, proteine, anticorpi e antigeni, ADA (anticorpi anti-farmaco), biomarcatori e biosimilari ed enzimi intatti, nonch\u00e9 analisi di campioni per studi preclinici e clinici. Prolytic pu\u00f2 effettuare analisi qualitative o quantitative di farmaci e metaboliti in sangue, plasma, urina, tessuti o altre matrici biologiche. Inoltre, pu\u00f2 anche condurre valutazioni farmacocinetiche compartimentali e non compartimentali. Come innovatore, Prolytic \u00e8 leader in progetti di cooperazione di ricerca finanziati dallo stato nel campo dello sviluppo di biomarcatori RNA e delle terapie avanzate.   <\/span><br \/><span style=\"font-size: 14pt;\">Fondata nel 2002 e con sede a Francoforte, Prolytic ha 17 dipendenti e 1.000 metri quadrati di strumentazione all&#8217;avanguardia.<\/span><\/p>\n<p><span style=\"font-size: 18.6667px;\"><a href=\"https:\/\/kymos.com\/it\/prolytic\/\" data-wpel-link=\"internal\">kymos.com\/prolytic<\/a><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Chi \u00e8 Kymos<\/strong><\/span><br \/><span style=\"font-size: 14pt;\">Kymos S.L. \u00e8 leader mondiale e uno dei primi dieci fornitori globali di servizi di test per biosimilari con anni di esperienza in biologici, piccole molecole e servizi completi sia in CMC che in bioanalisi. Organizzazione di laboratorio a contratto europea certificata GLP\/GMP, conforme GCP, ispezionata da EMA e FDA, specializzata in bioanalisi e CMC, Kymos fornisce studi completi di bioequivalenza, inclusi biowaiver per DP topici, bioanalitica di molecole piccole e grandi, ADA, test di rilascio di lotti per studi preclinici e clinici in Europa. Kymos offre anche servizi CMC per lo sviluppo di metodi, caratterizzazione, comparabilit\u00e0 di biosimilari e anni di esperienza con clienti biofarmaceutici in tutto il mondo.  <\/span><br \/><span style=\"font-size: 14pt;\">Fondata nel 2001 e con sede a Barcellona, Kymos ha 110 dipendenti e 3.000 m\u00b2 di strutture, con strumenti di ultima generazione. L&#8217;affiliata italiana ha altri 20 dipendenti e circa 1.000 m\u00b2 di strutture. Il fatturato congiunto delle tre aziende dovrebbe superare i 13 milioni di euro (15,1 milioni di dollari) nel 2020.  <\/span><br \/><span style=\"font-size: 14pt;\"><a href=\"https:\/\/kymos.com\/it\/\" data-wpel-link=\"internal\">Kymos<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":27424,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[263,255],"tags":[],"class_list":["post-27422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gruppo-kymos","category-notizia"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymos e Prolytic si fondono per diventare Kymos Group | Kymos<\/title>\n<meta name=\"description\" content=\"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymos e Prolytic si fondono per diventare Kymos Group | Kymos\" \/>\n<meta property=\"og:description\" content=\"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-28T08:11:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T20:11:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"494\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Kymos e Prolytic si fondono per diventare Kymos Group\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:11:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/\"},\"wordCount\":1009,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"articleSection\":[\"Gruppo Kymos\",\"Notizia\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/\",\"name\":\"Kymos e Prolytic si fondono per diventare Kymos Group | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:11:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"width\":900,\"height\":494,\"caption\":\"Kymos and Prolytic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymos e Prolytic si fondono per diventare Kymos Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/it\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/it\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/it\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymos e Prolytic si fondono per diventare Kymos Group | Kymos","description":"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/","og_locale":"it_IT","og_type":"article","og_title":"Kymos e Prolytic si fondono per diventare Kymos Group | Kymos","og_description":"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.","og_url":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/","og_site_name":"Kymos","article_published_time":"2020-09-28T08:11:26+00:00","article_modified_time":"2026-03-04T20:11:12+00:00","og_image":[{"width":900,"height":494,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Scritto da":"Joan Puig de Dou","Tempo di lettura stimato":"5 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/it\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Kymos e Prolytic si fondono per diventare Kymos Group","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:11:12+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/"},"wordCount":1009,"image":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","articleSection":["Gruppo Kymos","Notizia"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/","url":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/","name":"Kymos e Prolytic si fondono per diventare Kymos Group | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:11:12+00:00","author":{"@id":"https:\/\/kymos.com\/it\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Kymos S.L. e Prolytic GmbH annunciano la riuscita fusione strategica per integrare Prolytic nel Kymos Group.","breadcrumb":{"@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","width":900,"height":494,"caption":"Kymos and Prolytic"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/it\/news\/kymos-e-prolytic-si-fondono-per-diventare-kymos-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/it\/"},{"@type":"ListItem","position":2,"name":"Kymos e Prolytic si fondono per diventare Kymos Group"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/it\/#website","url":"https:\/\/kymos.com\/it\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/kymos.com\/it\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/it\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/posts\/27422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/comments?post=27422"}],"version-history":[{"count":3,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/posts\/27422\/revisions"}],"predecessor-version":[{"id":35231,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/posts\/27422\/revisions\/35231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/media\/27424"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/media?parent=27422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/categories?post=27422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/it\/wp-json\/wp\/v2\/tags?post=27422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}